Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 crossover study of dasiglucagon vs glucagon for insulin-induced severe hypoglycaemia in Asian adults and Japanese adolescents with type 1 diabetes
jRCT2071240050Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dasiglucagon in hypoglycaemia and diabetes mellitus type 1 (T1D) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Time to plasma glucose recovery (primary). Started Sep 2024; status: completed.
02
Drugs
dasiglucagon
03
Conditions
hypoglycaemiadiabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT2071240050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240050.